Kazia Therapeutics (NASDAQ: KZIA)

Last close As at 20/06/2024

1.32

0.04 (3.13%)

Market capitalisation

22m

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

View More

Balance Sheet

Forecast net debt (US$m)

6

Forecast gearing ratio (%)

224

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 7.1 28.2 (77.5)
Relative 3.2 19.1 (78.4)
52 week high/low US$6.0/US$0.5

Financials

Kazia Therapeutics has released its Q223 activity report and provided a business update for the quarter. Q2 was marked by increased preclinical efforts towards exploring the applicability and efficacy of paxalisib in non-central nervous system (CNS) oncology indications such as melanoma and other solid tumors, including breast cancer. Post-period, Kazia announced a A$4.5m fund-raise through a two-stage private placement of 40.9m new shares (25.4m unconditional shares and 15.5m conditional shares) at A$0.11 per share. Management intends to use the proceeds to support its development programs (including the paxalisib GBM AGILE study due to readout in H2 CY23) and working capital requirements. The period-end net cash balance stood at A$4.4m and this, along with the A$4.5m fund-raise, should provide headroom into H2 CY23, based on current burn rates.

Y/E Jun Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.7 (3.1) (3.1) (25.09) N/A N/A
2022A 0.0 (14.9) (14.9) (110.57) N/A N/A
2023E 0.0 (19.0) (19.0) (111.41) N/A N/A
2024E 10.8 (17.2) (17.2) (82.84) N/A N/A

edison tv

Healthcare

EVT801, Kazia’s second programme, and capital markets

edison tv

Healthcare

Paxalisib: Beyond glioblastoma and commercial opportunity

ADR Update

Healthcare

Kazia Therapeutics — Several upcoming catalysts

edison tv

Healthcare

Kazia Therapeutics: Edison Open House Healthcare 2022

edison tv

Healthcare

Kazia Therapeutics – introducing novel asset EVT-801

ADR Update

Healthcare

Kazia Therapeutics — Paxalisib Chinese rights licensed

edison tv

Healthcare

Kazia Therapeutics – Edison Open House interview

ADR Update

Healthcare

Kazia Therapeutics — Cantrixil final Phase I data reported

ADR Update

Healthcare

Kazia Therapeutics — An agile pivot

Update

Healthcare

Kazia Therapeutics — An agile pivot

edison tv

Healthcare

Executive interview – Kazia Therapeutics

ADR Update

Healthcare

Kazia Therapeutics — New indications for GDC-0084

Update

Healthcare

Kazia Therapeutics — New indications for GDC-0084

Outlook

Healthcare

Kazia Therapeutics — GDC-0084 Phase II underway

ADR Outlook

Healthcare

Kazia Therapeutics — GDC-0084 Phase II underway

Update

Healthcare

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Update

Healthcare

Novogen — GDC-0084 Phase II on track to commence Q417

ADR Outlook

Healthcare

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Outlook

Healthcare

Novogen — Anisina nixed, GDC-0084 on track for Phase II

Update

Healthcare

Novogen — Update 31 October 2016

ADR Update

Healthcare

Novogen — Update 11 May 2016

Update

Healthcare

Novogen — Update 9 May 2016